These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 1666324)

  • 1. Indications for the use of cytomegalovirus-seronegative blood products.
    Preiksaitis JK
    Transfus Med Rev; 1991 Jan; 5(1):1-17. PubMed ID: 1666324
    [No Abstract]   [Full Text] [Related]  

  • 2. [Leukocyte depletion and infection by cytomegalovirus].
    Mazeron MC
    Transfus Clin Biol; 2000 Jun; 7 Suppl 1():31s-35s. PubMed ID: 10919221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transfusion-associated cytomegalovirus infections.
    Adler SP
    Rev Infect Dis; 1983; 5(6):977-93. PubMed ID: 6318291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Transmission cytomegalovirus infection by blood transfusions].
    Mañez R
    Sangre (Barc); 1993 Jun; 38(3):201-4. PubMed ID: 8211545
    [No Abstract]   [Full Text] [Related]  

  • 5. Transfusion-transmitted cytomegalovirus infection.
    Bowden RA
    Hematol Oncol Clin North Am; 1995 Feb; 9(1):155-66. PubMed ID: 7737939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Is serologic screening necessary in the donor bloods for cytomegalovirus seronegative blood transfusion to risky patients?].
    Mutlu B; Günlemez A; Türker G; Gökalp AS; Willke A
    Mikrobiyol Bul; 2008 Apr; 42(2):337-41. PubMed ID: 18697432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant.
    Bowden RA; Slichter SJ; Sayers M; Weisdorf D; Cays M; Schoch G; Banaji M; Haake R; Welk K; Fisher L; McCullough J; Miller W
    Blood; 1995 Nov; 86(9):3598-603. PubMed ID: 7579469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transfusion-transmitted cytomegalovirus: behaviour of cell-free virus during blood component processing. A study on the safety of labile blood components in Switzerland.
    Voruz S; Gowland P; Eyer C; Widmer N; Abonnenc M; Prudent M; Masouridi-Levrat S; Duchosal MA; Niederhauser C
    Blood Transfus; 2020 Nov; 18(6):446-453. PubMed ID: 32203012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The incidence and consequences of cytomegalovirus transmission via blood transfusion to low birth weight, premature infants in north east Scotland.
    Galea G; Urbaniak SJ
    Vox Sang; 1992; 62(4):200-7. PubMed ID: 1322610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transfusion support using filtered unscreened blood products for cytomegalovirus-negative allogeneic marrow transplant recipients.
    Narvios AB; Przepiorka D; Tarrand J; Chan KW; Champlin R; Lichtiger B
    Bone Marrow Transplant; 1998 Sep; 22(6):575-7. PubMed ID: 9758346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation.
    Bowden RA; Sayers M; Flournoy N; Newton B; Banaji M; Thomas ED; Meyers JD
    N Engl J Med; 1986 Apr; 314(16):1006-10. PubMed ID: 3007984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytomegalovirus infection following stem cell transplantation.
    Einsele H; Hebart H
    Haematologica; 1999 Jun; 84 Suppl EHA-4():46-9. PubMed ID: 10907466
    [No Abstract]   [Full Text] [Related]  

  • 13. Epidemiology of cytomegaloviral infections: recommendations for prevention and control.
    Onorato IM; Morens DM; Martone WJ; Stansfield SK
    Rev Infect Dis; 1985; 7(4):479-97. PubMed ID: 2994198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytomegalovirus and blood transfusion.
    Tegtmeier GE
    Prog Clin Biol Res; 1985; 182():175-99. PubMed ID: 2994097
    [No Abstract]   [Full Text] [Related]  

  • 15. Congenital cytomegalovirus screening.
    Adler SP
    Pediatr Infect Dis J; 2005 Dec; 24(12):1105-6. PubMed ID: 16371874
    [No Abstract]   [Full Text] [Related]  

  • 16. Prevention of transfusion-transmitted cytomegalovirus infection.
    Pamphilon DH; Rider JR; Barbara JA; Williamson LM
    Transfus Med; 1999 Jun; 9(2):115-23. PubMed ID: 10354380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of filtered leukocyte-reduced blood products for prevention of transfusion-associated cytomegalovirus infection.
    Landaw EM; Kanter M; Petz LD
    Blood; 1996 Jun; 87(11):4910. PubMed ID: 8639866
    [No Abstract]   [Full Text] [Related]  

  • 18. Why is cytomegalovirus the most frequent cause of congenital infection?
    Lazzarotto T; Lanari M
    Expert Rev Anti Infect Ther; 2011 Oct; 9(10):841-3. PubMed ID: 21973293
    [No Abstract]   [Full Text] [Related]  

  • 19. [Cytomegalovirus hyperimmune globulin and cytomegalovirus-tested blood products--a pilot study in bone marrow graft recipients].
    Beelen DW; Neumann MC; Mahmoud HK; Henneberg K; Thraenhart O; Schaefer UW
    Immun Infekt; 1985 Sep; 13(5):229-32. PubMed ID: 2998980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survey on Transfusion-Transmitted Cytomegalovirus and Cytomegalovirus Disease Mitigation.
    Weisberg SP; Staley EM; Williams LA; Pham HP; Bachegowda LS; Cheng YH; Schwartz J; Shaz BH
    Arch Pathol Lab Med; 2017 Dec; 141(12):1705-1711. PubMed ID: 28849943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.